Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management

Table 1

Recommendation for NOACs cessation before elective procedure.

	Dabigatran		Apixaban		Rivaroxaban
	No important bleeding risk and/or adequate local hemostasis possible: perform at trough level (i.e., 12 hours or 24 hours after last intake)
Creatinine clearance	Low risk	High risk	Low risk	High risk	Low risk	High risk
≥80 mL/min	≥24 hours	≥48 hours	≥24 hours	≥48 hours	≥24 hours	≥48 hours
50–80 mL/min	≥36 hours	≥72 hours	≥24 hours	≥48 hours	≥24 hours	≥48 hours
30–50 mL/min	≥48 hours	≥96 hours	≥24 hours	≥48 hours	≥24 hours	≥48 hours
15–30 mL/min	Not indicated	Not indicated	≥36 hours	≥48 hours	≥36 hours	≥48 hours
<15 mL/min	No official indication for use